» Articles » PMID: 38667472

Analyzing Longitudinal Health Screening Data with Feature Ensemble and Machine Learning Techniques: Investigating Diagnostic Risk Factors of Metabolic Syndrome for Chronic Kidney Disease Stages 3a to 3b

Overview
Specialty Radiology
Date 2024 Apr 26
PMID 38667472
Authors
Affiliations
Soon will be listed here.
Abstract

Longitudinal data, while often limited, contain valuable insights into features impacting clinical outcomes. To predict the progression of chronic kidney disease (CKD) in patients with metabolic syndrome, particularly those transitioning from stage 3a to 3b, where data are scarce, utilizing feature ensemble techniques can be advantageous. It can effectively identify crucial risk factors, influencing CKD progression, thereby enhancing model performance. Machine learning (ML) methods have gained popularity due to their ability to perform feature selection and handle complex feature interactions more effectively than traditional approaches. However, different ML methods yield varying feature importance information. This study proposes a multiphase hybrid risk factor evaluation scheme to consider the diverse feature information generated by ML methods. The scheme incorporates variable ensemble rules (VERs) to combine feature importance information, thereby aiding in the identification of important features influencing CKD progression and supporting clinical decision making. In the proposed scheme, we employ six ML models-Lasso, RF, MARS, LightGBM, XGBoost, and CatBoost-each renowned for its distinct feature selection mechanisms and widespread usage in clinical studies. By implementing our proposed scheme, thirteen features affecting CKD progression are identified, and a promising AUC score of 0.883 can be achieved when constructing a model with them.

References
1.
Choe W, Choi E, Han K, Lee E, Lee S, Cha M . Association of metabolic syndrome and chronic kidney disease with atrial fibrillation: A nationwide population-based study in Korea. Diabetes Res Clin Pract. 2018; 148:14-22. DOI: 10.1016/j.diabres.2018.12.004. View

2.
Singh A, Kari J . Metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens. 2013; 22(2):198-203. DOI: 10.1097/MNH.0b013e32835dda78. View

3.
Lv J, Zhang L . Prevalence and Disease Burden of Chronic Kidney Disease. Adv Exp Med Biol. 2019; 1165:3-15. DOI: 10.1007/978-981-13-8871-2_1. View

4.
Noborisaka Y, Ishizaki M, Yamazaki M, Honda R, Yamada Y . Elevated Serum Gamma-Glutamyltransferase (GGT) Activity and the Development of Chronic Kidney Disease (CKD) in Cigarette Smokers. Nephrourol Mon. 2014; 5(5):967-73. PMC: 3955288. DOI: 10.5812/numonthly.13652. View

5.
Abutaleb N . Why we should sub-divide CKD stage 3 into early (3a) and late (3b) components. Nephrol Dial Transplant. 2007; 22(9):2728-9. DOI: 10.1093/ndt/gfm349. View